Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Monthly Archives: July 2022
Is the ISS an Ideal Place to Grow Billions of Stem Cells? Scientists Seem to Think So – iTech Post
Posted: July 19, 2022 at 1:56 am
Stem cell research has been considered a potentially thriving resource for a wide range of therapies for such diseases as Parkinson's Disease and heart disease. This is due to stem cells' ability to generate close to any type of cell in the body and their exceptional adaptability that make them effective tools to discover new treatments to fight deadly diseases.
While stem cell research has grown by leaps and bounds, there have been barriers to reaching this objective, particularly in producing an enormous amount of stem cells to realize these therapies. To overcome these, scientists conducted experiments on stem cells aboard the International Space Station. Why the ISS? This is because microgravity conditions in the ISS offer an ideal environment to explore new scientific methods and approaches, allowing researchers to hurdle logistic barriers to mass production of stem cells, potentially in the billions.
This is because patients may need billions of cells as the specific treatment may require. While on Earth, gravity makes it challenging to produce these cells in massive quantities, which these treatments need. As such, stem cell research and mass production is deemed more effective in space, with the ISS as an ideal place to make that happen.
Researchers at Cedars-Sinai Medical Center in Los Angeles has taken a giant leap to realize producing a type of stem cell in massive batches, a press announcement said. This stem cell can generate any type of cell in the bodytha can be used to make treatments for a number of diseases. One of its researchers, Dhruv Sareen, donated his own stem cells for the stem cell experiment in the ISS. Sareen's cells arrived aboard a SpaceX resupply mission - the SpX-25 dragon cargo mission - to the ISS over the weekend.
The experiment is the latest research project that involves shooting stem cells into space. Some, like this one, aim to overcome the terrestrial difficulty of mass producing the cells. Others explore how space travel impacts the cells in the body. And some help better understand diseases such as cancer.
Read Also:Stem Cell Transplant Sees Mice Regaining Memory And Learning Capabilities
In the previous stem cell research projects, the U.S., China and Italy brought to space various types of stem cells, including research on the effects of microgravity on cell-level heart function by Dr. Joseph Wu of Stanford University, director of the Stanford Cardiovascular Institute. Wu led a series of programs onn of Washing space-based stem cell research last year.
Earth-based applications have so far been limited.
Currently, the U.S. Food and Drug Administration (FDA) has only approved stem cell products that carry blood-forming stem cells originating from umbilical cord blood to treat lymphoma. Stem cell treatments derived from stem cells sent to space have yet to be approved, according to Jeffrey McMillan of Washington University in St. Louis, Missouri.
The only stem cell-based products approved by the Food and Drug Administration contain blood-forming stem cells from umbilical cord blood for patients with blood disorders such as certain cases of lymphoma. There are no approved therapies using the kind of stem cells being sent to space or others derived from them, according to biomedical engineering expert Jeffrey Millman of Washington University in St. Louis, Missouri in an Interesting Engineering report.
McMillan noted that with present technology, even with FDA approval, capacity to manufacture these treatments is unattainable.
This is because large bioreactors are needed to produce stem cells on Earth. And these cells need to be stirred vigorously, so they don't stick together or precipitate to the bottom of the tank. The stirring process could also damage the cells. In microgravity, no such force is exerted on the cells, thus they are able to grow using a different approach.
The Cedars-Sinai research team sent a shoebox-sized container holding pluripotent stem cells for their NASA-funded experiment on the ISS. The container holds pumps and chemical solutions needed to keep the stem cells alive for four weeks, the Interesting Engineering report further said. The same experiment will be carried out on Earth for comparison. In about five weeks, the box sent to space will be brought back to Earth through the same SpaceX capsule it was sent to space on. The mission will help scientists directly evaluate results in space and on Earth in a short timeframe. This will offer valuable new insight that could help launch a burgeoning field of medical research.
Related Article: Stem Cell Therapy: Miracle Cure Discovered For Girl With Cerebral Palsy
The rest is here:
Is the ISS an Ideal Place to Grow Billions of Stem Cells? Scientists Seem to Think So - iTech Post
Posted in Missouri Stem Cells
Comments Off on Is the ISS an Ideal Place to Grow Billions of Stem Cells? Scientists Seem to Think So – iTech Post
UM-Dearborn graduate hopes to make it to space – Dearborn Press and Guide
Posted: July 19, 2022 at 1:56 am
Samantha Snabes has wanted to be an astronaut for so long she doesnt remember a time when that wasnt the goal. Its not a totally unique childhood dream, of course, but Snabes has proved durable.
Now 41, she still very much wants to go to space, and in fact, has measured many life choices against whether they can help her get there. That focus has led her to do all kinds of bold things, starting from an early age. When she was 8 years old, she went to Space Camp, and after she got home, she cross referenced the astronaut directory in one of the take-home brochures with the white pages, calling up any astronauts with Michigan phone numbers. A few days later, Tony England, a veteran of the Apollo and Space Shuttle era and the now-retired dean of UM-Dearborns College of Engineering and Computer Science, left her a voicemail. It led to a memorable meeting between the two and some practical advice: I asked him what I needed to do to become an astronaut, and he said go to college.
Snabes held tight to Englands advice, but getting to college wasnt going to be straightforward. Aside from two aunts, no one in her family had a college diploma, and she was going to have to get creative to find the financial resources for college. The thing she had going for her was she was a standout student: Snabes was the valedictorian of her class and Wayne-Westlands Senior of the Year. So using money she saved from grooming dogs and cleaning horse stalls, she sent in her college applications. She got in almost everywhere she applied including Cornell. She assumed the admissions would come with offers of financial support, but the only place offering a scholarship was a college in Missouri. Her grandparents encouraged her to go for it, and after graduation, she packed up her things and headed to Springfield.
Snabes remembers many things about college being a struggle. She never had money for the current editions of textbooks, so she got by with older versions and loaners from the library. Often the reason her grades were so erratic was her out-of-date books literally didnt contain the required reading.
I think the culture is a lot different now, but I dont think it even really occurred to me to ask for help, Snabes said. I didnt have the resources and it felt like there was a stigma around that. Everyone else had their laptops, the right books, and seemed to know all these things that I didnt. I think its just sort of who I am, but I tried to figure things out on my own and push my way through it.
Despite the challenges, Snabes ultimately leveraged a lot of credits she earned there on scholarship into a transfer to UM-Dearborn. Continuing her education meant taking out lots of student loans, and like many first-gen students, she got tripped up navigating the conventions of the university system. She remembers that when she first transferred, someone encouraged her to pick a major and she didnt even know what a major was. She said astrophysics, one the university didnt offer, and then chose Biology based on someones suggestion that it might be a good fit given her love of science. Knowing of her ultimate dream, one of her professors suggested she should try to get some research experience, and she found a spot doing bench work in a start-up at a UM-Ann Arbor lab that was working with stem cells.
She half-jokingly says she was the janitor of the lab team, because her entry-level spot meant she did a lot of cleaning and prep work. But Snabes really shined in the lab. Her particular role involved using specialized hardware to grow stem cells, and she viewed keeping them alive as a personal challenge. Often she would drive back and forth between Detroit and Ann Arbor twice a day just to check on my cells, and her lab notebooks from that time are decorated with doodles of Thanksgiving turkeys and Christmas trees. At one point, their team set a record for keeping cells alive and regenerating in the device they were testing for more than a year. In fact, Snabes played a crucial part in that success. When she joined the team, the project was in a Phase II trial, and they were facing some challenges with lower-than-expected cell counts. One day, she asked if the trouble they were having keeping the cells alive might have something to do with the silver in the felt matrix they were growing them on. One of the investigators asked what she was thinking and she explained she remembered from her days making Halloween costumes for her younger siblings that felt often contains a silver ion, which gives it some antimicrobial properties. Ultimately it led to a discovery that the team had been unknowingly using off-the-shelf hobby-grade felt that did in fact contain silver. When they switched to medical grade, the cells took off, and so did the then-stalled project.
Snabes prowess in the lab ultimately led to her getting her name on the patent and another big opportunity. The start-up team had made rights to the technology available so others could build on the work, and the supervisor whom Snabes worked mostly closely with happened to be a serial entrepreneur. One day, the two went out to lunch and he asked if shed be interested in using the technology to start a company. The idea, hatched in a Korean restaurant in an Ann Arbor strip mall, eventually grew into Bioflow, which they launched in 2006. Over the next few years, they built up a client roster for their cell culture systems, but for a variety of reasons, selling the company became a better proposition than continuing to build it. She said looking back, they didnt get the best deal, but it allowed them to pay off their debts and get a fresh start with other opportunities.
For all of Snabes talents, instincts, and worth ethic in the lab, it was still just a means to an end in some ways. Getting into the astronaut program was still on her mind, and she was still making unconventional decisions to get there. During her time at UM-Dearborn, she had applied several times toNASAs Microgravity University, a program where undergraduates get to conduct experiments in a low-gravity environment. The highlight is a chance to ride in the Vomit Comet NASAs modified KC-135 aircraft that flies to 33,000 feet and then sharply nose dives for 30 seconds so passengers can experience something very close to weightlessness. Snabes caught NASAs attention with her first pitch: A blood clotting experiment that proposed using herself as a test subject. The advisers wrote back they couldnt sanction a project where she cut herself, and she wouldnt have sufficient time for the blood to clot anyway. But they loved her inventiveness and encouraged her to assemble another student team and apply again. The second time, she and her group from UM-Dearborn got in. But then federal funding snags delayed their scheduled trip in the Vomit Comet. That was a big deal, because Snabes was set to graduate and the program was only for undergrads. So she postponed her graduation, enrolling in enough classes to complete a Psychology minor. Additional student loan debt was more than worth the chance to fly.
Snabes ride in the Vomit Comet stands out as one of the highlights of her life. The photo of her, arms across her chest, somersaulting in the air, a relaxed smile on her face, is still her LinkedIn profile picture. Its worth mentioning that many people dont have such a good time. The Vomit Comet is so named because most people get violently nauseous when their body is suddenly propelled into near weightlessness. (For Snabes, that didnt happen until the celebratory meal afterward in which she says she ate way too many Chinese donuts.) The reason why the moment is still so important to her is straightforward enough: Given the competitiveness of the astronaut program, she knows she might not ever get in, and spinning weightlessly for a few seconds might be the closest she ever gets to space. The mental images of it all are still thrilling and vivid, exactly the feeling you have when youre flying in a dream. Only for Snabes, she experiences it with the realness of memory.
The experience also broke open a new series of opportunities. Snabes didnt know it at the time, but NASA was looking to recruit a couple people from the program to advocate on Capitol Hill about the value of the space program to regular citizens. She was happy to do it, and in the course of that work, she learned that a life sciences group at NASAs Johnson Space Flight Center needed a strategist ideally, a hip, under 30-something, who was a successful entrepreneur, had recently exited a company, had an MBA, and is passionate about space. Having recently started an MBA through UM-Dearborns online program, Snabes resume checked all the boxes, and in the end, she didnt even have to formally interview for the job. Once she had an in at NASA, other dominos started to tumble. Her job description at the agency was so loose, it gave her carte blanche to explore almost anything that sounded interesting to her. More importantly, she was finally fully amongst her people engineers, scientists and innovators who could talk all day and all night about big ideas and how they could change the world. Her volunteer time with Engineers Without Borders (EWB) was particularly formative, and through contacts with EWB and NASA, she finally got a chance to do something she never had the money to do: travel. As the social entrepreneur in residence for NASA headquarters, she traveled to Rwanda, Nicarauga and Mexico, exploring opportunities for the agency to do more social impact work. Looking back, it was a big turning point. What I realized is that we spend a lot of time and money trying to get resources into countries, and all these brilliant people from NASA were training people on whatever solutions we had, she says. But then Id see abandoned mounds of medical equipment that were the wrong voltage or couldnt be maintained sitting outside of a hospital. For Snabes, it seemed like there had to be a better way.
Around this time, Snabes and some like-minded friends and colleagues were getting really into something that could be part of that better way. Many of the patents on key parts of 3D printing technology were expiring, allowing researchers and entrepreneurs to build on the hardware in new ways. She was particularly interested in the idea of open-source 3D printing a paradigm in which the designs, software and printing technology could be deployed inexpensively to people, allowing communities to manufacture solutions for real problems. Enabling people to make their own things at lower costs was the exact antithesis to the bigger budget aid strategies Snabes had seen falter at times. The only problem was the technology at the time was limited, particularly by size: Inexpensive 3D printers were still pretty small and could only print small things. People would be really into the idea, but then theyd ask to see an example of something you could make, and inevitably someone would have something small, like an iPhone case or a Yoda head. They were still a ways away from being able to print things folks told her they were interested in, like limb prosthetics, birthing stools, composting toilets, and tools, to name a few.
Snabes realized theyd have to literally start thinking bigger. A larger printer could print larger, more useful stuff, and hours and hours of conversations with her friends and colleagues eventually coalesced around an aspirational goal to design and build a large-format 3D printer the size of a toilet for under $10,000. At the time, she said she didnt see it as starting her next company, and in fact, she shopped the idea around at NASA and EWB first, thinking they might go for it. When it didnt find a home with either, they scored $40,000 to build a prototype, which they debuted at SXSW at the Start-up Chile tent in 2013. A writer from TechCrunch was one of the first to see it demoed and put it onthe front page of the website. In less than two days, their Kickstarter campaign was fully funded.
With the spike of unexpected interest, Snabes and her co-founder dove right into starting the business. Nowre:3Dships its large-format Gigbot printers all over the world, including a new model that can print directly from plastic waste. For every hundred they sell, they also give one away to a person or group using it for social good. Their website is full of interesting testimonials. Theres aNigerian engineer using his Gigabot to develop new filament technologyand spur micro-manufacturing. A Kenyan charity is printing parts torepair medical equipment and water distribution infrastructure. In Portland, a nonprofit is using theirs to make some prettyepic custom costumes for kids in wheelchairs.
Though re:3D has garnered a ton of attention and goodwill, Snabes is clear that the business is still firmly in the start-up phase. Competition for large-format printing has grown since they started the business, and recruiting investors for a company devoted to a social mission is a different endeavor than if they were just trying to make money. Were definitely not a high-growth company, so whether or not you see us as successful depends, I guess, on how you measure success, Snabes says. But she says it never occurs to her to doubt the mission, and feels thankful that all the unexpected plot twists in her life have led her here. I recognize that as a woman who didnt have a ton of financial resources to draw on and who didnt grow up with an expectation to go to college, things could be working out differently. Now, Ive had the chance to start two companies, and I basically get to get up everyday and do whatever I want. Thats incredibly rare, and Im really humbled that thats my life right now.
She also hasnt given up on space, and is still doing everything she can to make herself an attractive astronaut candidate. Its completely possible that given the current interest in long-range space travel, experiments with 3D-printing could well be her ticket there. And though re:3D can feel all-consuming, she still makes time to serve as a major in Mississippis Air National Guard. She enlisted 13 years ago on her lunch break at NASA partly to help pay bills, partly to make her application to the astronaut program stronger. But its since turned into a big part of her life. There are lots of stereotypes about the Guard, she says, but for her, its another community of problem solvers who ultimately want to help people. Whether its the Guard, or her 3D-printing work, or the sum of all her adventures thats the difference-maker this time, she figures she has one more good shot before shes too old to be an astronaut. However it shakes out, her hustle has already fueled a wild ride.
See the original post here:
UM-Dearborn graduate hopes to make it to space - Dearborn Press and Guide
Posted in Missouri Stem Cells
Comments Off on UM-Dearborn graduate hopes to make it to space – Dearborn Press and Guide
Testosterone Therapy Improves Erectile Function and Libido in …
Posted: July 11, 2022 at 2:51 am
Curr Opin Urol. Author manuscript; available in PMC 2018 Nov 1.
Published in final edited form as:
PMCID: PMC5649360
NIHMSID: NIHMS910261
aBaylor College of Medicine, Houston, TX
aBaylor College of Medicine, Houston, TX
bScott Department of Urology, Baylor College of Medicine, Houston, TX
cCenter for Reproductive Medicine, Baylor College of Medicine, Houston, TX
bScott Department of Urology, Baylor College of Medicine, Houston, TX
aBaylor College of Medicine, Houston, TX
bScott Department of Urology, Baylor College of Medicine, Houston, TX
cCenter for Reproductive Medicine, Baylor College of Medicine, Houston, TX
Erectile dysfunction (ED) and decreased libido are common complaints in the older male population. Recent studies have elucidated the role testosterone therapy (TTh) can play in men with low testosterone levels. The aim of this review is to provide an overview of these findings and the utility of TTh. We specifically examine the role of TTh on erectile function, co-administration with phosphodiesterase type 5 (PDE5) inhibitors, and libido.
Recent publications suggest that TTh improves mild ED, though may be less useful in men with more severe ED. In men unresponsive to PDE5 inhibitors and with mild ED, TTh can further improve erectile function. Testosterone therapy has also shown consistent benefit in improving libido in men with low testosterone levels at baseline, with no additional improvements once testosterone levels are normalized.
The available literature supports a role for TTh in men with low testosterone levels, ED, and low libido, with symptomatic improvement in these men.
MeSH Keywords: Testosterone, Erectile Function, Phosphodiesterase 5 Inhibitors, Hypogonadal men
Multiple longitudinal studies have observed that as men age, they experience a decline in total serum testosterone beginning in the third decade of life [1, 2]. By age 70, 30% of men will have low testosterone levels [2]. The symptoms of low testosterone include decreased libido, erectile dysfunction (ED), decreased energy, depressive symptoms, and fatigue [3]. These symptoms can be frustrating to men, and can be at least partially reversed with testosterone therapy (TTh). In this review, we summarize the recent literature examining the relationship between low serum testosterone levels, ED, and decreased libido.
To identify articles for this review, the following search terms were used in Medline: testosterone, testosterone replacement therapy, erectile dysfunction, and libido. Relevant and recent articles were identified and presented in this review. Articles published within the last 18 months were prioritized in this review.
ED affects 1 in 5 men, with this frequency increasing with age and the prevalence of co-morbidities [4, 5]. The National Institute of Health (NIH) defines ED as the inability to achieve or maintain an erection that is satisfactory for sexual performance [6]. Subjective erectile function can be assessed using validated questionnaire metrics including the international index of erectile function (IIEF) with the erectile function domain (IIEF-EF) being the most specific for assessing ED. The IIEF-EF consists of 6 questions that inquire about frequency and hardness of erections, ability to penetrate during intercourse, ability to maintain an erection during intercourse, ability to maintain an erection to completion of intercourse, and confidence in a mans ability to get and maintain an erection [7]. The severity of ED is then classified as mild, mild to moderate, moderate, and severe dysfunction. The IIEF-EF is often used in studies to trend changes in erectile function, with a change of 2 IIEF-EF points being clinically significant for men with mild ED. The minimal clinically important differences (MCID) for moderate and severe ED are a change of 5 and 7 IIEF-EF points, respectively [8].
Erection requires a combination of vascular, neurologic, psychologic, and hormonal factors. Erections are initiated when nitric oxide and other neuroendocrine factors induce relaxation of the smooth muscles of the cavernous arteries and tissues resulting in increased penile blood inflow. As the corpus cavernosum fills with blood, the veins that drain the corpus cavernosum are compressed, resulting in maintained turgidity [9]. This initial release of nitric oxide is mediated in part by testosterone [10]. While evaluating neurologic, vascular, and psychologic factors can be difficult during a clinical visit, a hormonal etiology of ED can easily be assessed by measuring morning serum testosterone levels. The evaluation of testosterone levels in men with ED is recommended by the European Association of Urology guidelines and is indicated in select men with ED per American Urology Association guidelines [11, 12].
Numerous studies have examined the relationship between testosterone levels and erectile function. In cross-sectional studies, men with low testosterone (defined by the US Food and Drug Administration as levels less than 300 ng/dL) have a greater prevalence of ED when compared to men with normal testosterone levels [1315]. Studies have observed that men who have been placed on androgen deprivation therapy (ADT) for prostate cancer have a dramatic reduction in erectile function with a decrease in testosterone levels [1618]. Finally, numerous randomized controlled trials (RCTs) have demonstrated that erectile function improves when testosterone is given to men with low testosterone levels [1924].
In the past few years, several studies have shown that testosterone levels and erectile function are positively correlated. The recently published Testosterone Trials a set of RCTs of 790 men with late onset hypogonadism randomly assigned to either testosterone gel or placebo demonstrated that after 1 year of treatment that men who used testosterone gel had an IIEF-ED score 2.64 points [95% Confidence Interval (CI): 1.06 4.02] greater than men who had been assigned to the placebo arm [24]. It is important to note that men enrolled in this study on average had moderate ED, and so this improvement in erectile function was not considered clinically significant.
In early 2017, Corona et al. performed meta-analysis of 14 RCTs that studied the effect of TTh on erectile function in men with late onset hypogonadism, and compared pre- and post-IIEF scores [25]. Overall, when compared to placebo, TTh provided only a modest improvement in IIEF-EF, as the mean difference between groups was 2.31 points. The mean change in IIEF-EF, however, was greater when data were stratified by baseline testosterone level. In primary studies using a testosterone threshold <8 nM (231 ng/dL), IIEF-EF increased by 2.95 points, whereas in primary studies with testosterone threshold of <12 nM (346 ng/dL), only a 1.47 point increase in IIEF-EF was observed [25]. Given that a greater improvement in erectile function was observed in studies using a lower testosterone threshold, this supports the theory that once a threshold of normal testosterone level is achieved, higher testosterone levels do not further improve erectile function [26]. This definitive study by Corona et al. also suggests that TTh may be a useful monotherapy in men with mild ED.
Numerous studies have found that phosphodiesterase type 5 (PDE5) is upregulated in the penis by androgens [27, 28], and when animals are castrated, a decline in both penile nitric oxide and PDE5 levels are seen [2830]. These early studies support the possibility that men with low testosterone may have a relative deficiency of PDE5, resulting in lower efficacy of PDE5 inhibitors [31]. In a randomized controlled trial by Shabsigh et al., dual treatment with sildenafil and testosterone was more effective than monotherapy with sildenafil for men with testosterone levels <400 ng/dL who had previously failed a trial of PDE5 inhibitors. Men receiving both testosterone and PDE5 inhibitors had an improvement of 4.4 IIEF points from baseline to 4 weeks while those receiving monotherapy only saw an increase of 2.1 IIEF-EF points (p=0.029) [32].
While Buvat et al. observed a positive effect in hypogonadal PDE5 inhibitor non-responders, other RCTs have not observed such a positive effect. In a 2012 RCT, Spitzer et al. studied 140 men on sildenafil and then randomly assigned them to either receive testosterone or placebo gel. All men had a testosterone level <330 ng/dL or a free testosterone level <50 pg/mL. At 14 weeks, those on dual therapy had an IIEF-EF score 1.01 points higher than those receiving sildenafil plus placebo gel (p=0.36). This study demonstrates that the giving testosterone to men who respond to PDE5 inhibitors may not further improve erectile function after normalization of testosterone levels. However, there is growing evidence supporting the use of testosterone in men with low testosterone and mild ED, especially in those who were previously non-responsive to PDE5 inhibitors [33, 34].
These recent studies suggest that TTh may be most effective as monotherapy in improving erectile function in men with mild ED, but not in men with more severe ED. Early studies have shown that TTh can improve the response to PDE5 inhibitors in non-responders.
Libido, or sexual drive, is affected by a multitude of factors, including physiologic ones, such as a defect in the hypothalamic-pituitary access or depression, or environmental ones, such as marital discourse or anxiety [3, 35, 36]. Changes in libido can variably affect individuals, with a wide range of clinical presentations. Longitudinal studies have found that libido declines with increasing male age [35]. When assessing libido, many studies use the sexual desire (SD) domain of the IIEF (IIEF-SD), which asks men to two libido-related questions: Over the past 4 weeks, how often have you felt sexual desire? and Over the past 4 weeks, how would you rate your level of sexual desire? Like the IIEF-EF domain, the IIEF-SD questions can be used to diagnose mild, mild to moderate, moderate, and severe dysfunction [7]. Other studies have used their own scale, such as the Sexual Arousal, Interest and Drive scale (SAID) a validated patient reported outcomes measuring 5 scored items, including sexual thought, arousal, as well as interest and drive [37].
Several early studies have demonstrated that TTh improves libido [38, 39]. Recently, the Sexual Function sub-trial of the Testosterone Trials examined sexual desire. This placebo-controlled trial included 470 men aged 65 years or older with testosterone levels less than <275 ng/dL [24]. When assessing the impact of TTh on sexual symptoms, the authors used the Derogatis Interview for Sexual Function-Sexual Desire Domain, comprised of 25 scored items, and found that libido improved proportionately with increase in testosterone levels, with an effect size of 0.44 [95% Confidence Interval: 0.32 0.56] [40]. Interestingly however, these trials found no threshold below which libido was universally affected for all men in the study.
The results of the largest placebo-controlled multicenter trial assessing the effect of testosterone on sexual function in hypogonadal men (715 men, 18 years of age and older) were published in 2016. Brock et al. found that 60 mg of topical testosterone 2% gel applied daily resulted in a significant increase in testosterone levels as well as libido, as measured using the SAID scale after three months of treatment. The study examined a cohort of hypogonadal men with a mean age of 55. Though not placebo-controlled beyond the third month, the open label continuation of the trial for both placebo and active treatment groups showed continued improvement in sexual function at 9 months when on continuous TTh, with no new adverse events [23]. In the group initially treated with placebo, 60% of men achieved normal testosterone levels at the end of the open label study, compared to 66% of the participants on TTh for the duration of the trial. Interestingly, the group that had received placebo before the 3-month time point and later placed on the open-label TTh achieved the same libido improvements as the group that had been on TTh for the entire 9 months. This finding suggests that benefits of TTh on libido plateau after 3 months of therapy. However, the study lacked a true control arm during the open-label portion of the trial, limiting the ability to make this conclusion. Furthermore, a post hoc analysis of the trials outcomes after 3 months further revealed that a lower testosterone level at the start of treatment and higher plasma concentration achieved at the end of treatment were associated with a greater patient reported improvement in libido [41].
The Corona et al. meta-analysis also assessed the impact of TTh on libido in hypogonadal men, finding that for 1,269 men across 14 randomized, placebo-controlled trials, the IIEF-SD significantly improved (p=0.001) [25]. These findings suggest that TTh may be more effective in improving sexual desire than in improving erectile function in men with moderate or severe ED. Citing previous studies that had failed to show improvements in libido on therapy, Corona et al. highlighted that many of these studies did not specifically examine a population with low testosterone at baseline and that in eugonadal men, TTh may be less beneficial in improving libido.
While TTh can improve libido, it is not without its risks [42]. Due to the wide-spread use of testosterone-related products for seemingly age-related symptoms and the potential cardiovascular risk, the FDA has commissioned a large clinical trial to assess the safety of testosterone products [43]. A joint patient-physician decision should be made whether the potential improvement in erectile function, libido, and energy with TTh outweighs the potential side-effects in each individual patient.
Many studies have demonstrated that TTh significantly improves libido in men. Moving forward, large RCTs specifically studying older men for more than a year of treatment are needed to better determine at what testosterone thresholds men demonstrate improvements or decrements in sexual function and desire. Finally, current measures of evaluating libido are either very narrow in their scope or not validated. As such, future work should focus on more clearly defining the impact of TTh on libido.
In men with low testosterone, normalizing testosterone levels has multiple benefits, most notably improved libido and improved erectile function when used as monotherapy in men with mild ED. For the latter, TTh is especially promising in hypogonadal men with mild ED who are unresponsive to phosphodiesterase-5 inhibitors. Testosterone therapy may be ineffective in men with moderate and severe ED, as the etiology for these more severe pathologies often include advanced diabetes, radical pelvic surgery, or severe neurologic damage. In these cases, a hormonal factor is often not the primary cause of dysfunction, and thus while TTh should be considered, other treatments are likely to be more effective.
Key Points
Testosterone replacement monotherapy can improve erectile function in men with mild ED, but not moderate and severe ED.
In men with low testosterone who are unresponsive to PDE5 inhibitors, normalization of testosterone levels can improve the response to PDE5 inhibitors.
Testosterone therapy improves libido in men with low testosterone.
Funding
A.W.P. is a National Institutes of Health K12 Scholar supported by a Male Reproductive Health Research Career Development Physician-Scientist Award (HD073917-01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Program (to Dolores J. Lamb).
Read more:
Testosterone Therapy Improves Erectile Function and Libido in ...
Posted in Testosterone Replacement Therapy
Comments Off on Testosterone Therapy Improves Erectile Function and Libido in …
Low Testosterone and What You Can Do About It – The Epoch Times
Posted: July 11, 2022 at 2:51 am
Its possible you dont have the energy, libido, or mood you used to. There can be several reasons, but one may have to do with dropping testosterone.
Testosterone is a hormone found in all humans. However, it plays a far more prominent role in men than women. It plays a role in sex drive, bone and muscle mass, fat storage, and red blood cell production. It may also affect a mans mood.
Testosterone typically peaks in a mans 20s or early 30s before it starts tapering off slowly over time. But everybodys baseline testosterone level is different. Some men are born with a lot of testosterone, while others are born with less. Normal testosterone can be anywhere from 280 to 1,100 nanograms per deciliter (ng/dL), which is a huge range.
So, somebody who has 1,100 ng/dL may feel it a lot more if levels get to 950 ng/dL than someone who starts with 500 ng/dL and sees it drop to 100 ng/dL. The difference may be more pronounced.
What might it feel like?
Low testosterone may create some of the following symptoms:
Youll only learn if you have low testosterone through blood tests, and youll only understand the rate its dropping with several tests used to track changes over time.
What can you do about it? There are a few things that may halt testosterone loss or at least slow it.
Diet and exercise can both play a role in testosterone levels. Weight training is associated with higher testosterone, and so is eating a nutrient-rich diet that is low in processed food. Fruits, vegetables, nuts, lean proteins, legumes, etc., is the way to go.
Managing weight may also help.
Testosterone replacement therapy, or TRT, is a procedure that can help, as well. It is still under study, but talk to your doctor if you believe low testosterone affects your quality of life.
Mat Lecompte is a health and wellness reporter for Bel Marra Health, which firstpublishedthis article.
View post:
Low Testosterone and What You Can Do About It - The Epoch Times
Posted in Testosterone Replacement Therapy
Comments Off on Low Testosterone and What You Can Do About It – The Epoch Times
Men Share The Costly Lengths They’ve Taken To Prevent Balding – HuffPost
Posted: July 11, 2022 at 2:47 am
As he was approaching 25 about a decade ago, David DiMuzio looked in the mirror and generally liked what he saw. But then there was his hairline: thinning and creeping backward, it looked like it belonged to a completely different guy one that was at least a few decades older than DiMuzio.
My hair felt like it was the only thing in my life that was working against me, said DiMuzio, a 36-year-old singer songwriter. Id look in the mirror and my hairline didnt feel like it should be my hairline. This should be the hairline of a guy whos like 60 years old.
DiMuzio was hitting his stride as a musician in the Philippines; his songs often ranked high on MTV music video countdowns in the country. Still, looking in the mirror, he couldnt shake the feeling that his hairline was holding him back professionally and personally.
With some research and consultations, DiMuzio found out he was a Norwood 5 on the Hamilton-Norwood scale, a classification system that uses a 1 to 7 scale to gauge hair loss.
A Norwood 5, he learned, is considered an advanced stage of baldness in men.
Demoralized by that number, he sought out a hair transplant. In search of more fullness, he decided to get another transplant, this time with a different surgeon. (Its not uncommon for hair transplant patients to undergo multiple surgeries.)
The second was problematic. The surgeon lost his license in Tennessee not long after performing DiMuzios surgery, and he went overboard with the musicians hairline.
He went well outside what is considered the safe zone in taking tissue from the back of my head and transplanting it to the front, DiMuzio told HuffPost. Because of that, I have a larger scar than I should, and it was not as successful of surgery as it should have been.
Since then, DiMuzio has gone on to correct the shoddy work. A few weeks ago, he had his fifth transplant. He also takes Finasteride (the generic name for Propecia) and minoxidil (the generic name for Rogaine) and uses an iRestore laser cap for hair growth. Hes happy with this hair today.
Even the scar is covered up by hair, and the hair looks great now, he said.
Of course, it came at a steep cost. The singer has spent $35,000 of his own money; two of his five surgeries were offered to him free by doctors hoping to make an appearance on his popular YouTube channel Hair Loss Hope, where he doles out advice to the young and follicly challenged.
There are more young guys concerned with their hairline than youd expect. Like many other procedures including nose jobs and Brazilian butt lifts, there was an uptick in patients requesting hair transplants during COVID. The lockdown meant you didnt have to worry about a coworker or friend seeing your bandaged-up head.
Dr. Marc Dauer, a hair restoration surgeon who practices in Los Angeles and New York City, told the New York Times that at the peak of the pandemic, his offices saw a 30% surge in hair transplant procedures and a 50% increase in transplant consultations.
But even before the pandemic, the demand for hair transplants was high. The hair restoration industry is projected to reach over $12 billion in 2026. The increase in stress-induced hair loss that came with the pandemic will probably only add to those numbers.
The patients coming in are getting younger and younger, too. These are guys concerned about looking Instagram perfect and not wanting to have to hatfish on Bumble or Tinder. (A clever play on catfishing, a guy who hatfishes looks great on screen, but strangely, hes wearing a hat in all of his photos.)
A bald person will listen to anyone who gives tips about hair growth.
- Amir ur Rehman, a 29-year-old engineer from Dubai who has had three hair transplants
On Facebook groups about hair loss and Reddit forums like r/tressless, young people commiserate over premature hair loss (aka the Norwood Reaper) and relay their experiences with different hair-restoration clinics around the world. (When it comes to hair tourism, Turkey is a hot spot.) They debate what procedures they suspect celebrities like Matthew McConaughey, LeBron James and Chris Evans have undergone through the years and analyze each others post-op pictures.
These robust online conversations have led people as young as 17 into plastic surgeon Monica Kieus office, looking for a consultation. Its worth noting here: Male pattern baldness can start showing as early as your late teens, but typically, hair specialists dont recommend a hair transplant for people under the age of 25 since your hairline likely hasnt settled yet and you dont quite know what youre working with.
As many aesthetic procedures are becoming more common and accepted, I have noticed younger patients seeking out hair restoration therapy, Kieu, whose office is in Newport Beach, California, told HuffPost. Although women are also seeking out hair transplants, the majority of my patients are still men between the ages of 20-60.
Jan Oliva, a 22-year-old from Southwest Florida, got his hair transplant under the cover of lockdown last year. Oliva went to the Dominican Republic another hair transplant hotspot for his work.
I first started noticing my receding hairline when I was around 16 and ever since then it was definitely a factor that affected my self esteem, he told HuffPost. It wasnt until last year that I decided to do some research on hair loss treatments.
Oliva had FUE follicular unit extraction. Its a procedure where the hair follicles are transplanted from the back of your head to your hairline without leaving any noticeable scarring. Over the years, FUE has become more popular than the follicular unit transplantation (FUT) the older procedure where the surgeon and technicians take a strip of skin from the back or the side of the scalp and then extract the hair follicles.
In the U.S., the FUE hair transplant could run you anywhere from $4,000 and $15,000 per session. Oliva said his surgery in the Dominican Republic came out to $2,800.
He found out about the surgeon on TikTok, another place where young men and some women regale others with their experiences with hair transplants, replete with images of the slightly unnerving looking immediate aftermath. (Almost every patient deals with some facial swelling and swelling of the scalp after a hair transplant.)
Now he makes hair restoration TikToks himself.
Im very happy with the results, he said. I might actually have to do it again because I only did my hairline.
Amir ur Rehman, a 29-year-old engineer from Dubai, also got his hair transplant when he was on the younger side.
At 23 years old, he felt way too young to be bald and he was sick of his phone resurfacing photos of him on this day in 2013 when he still had a healthy, enviable crop of hair.
His wife was fine with him balding in his early 20s, but it didnt sit right with him. Some people suggested I should wear a wig, but youll never get satisfaction wearing a wig, he said.
He tried shampoo after shampoo and took advice from anyone whod offer some, but nothing seemed to work.
I got scammed in Dubai by some random guy who offered me some herbal medicine the hair scam is very famous in Dubai, he said. A bald person will listen to anyone who gives tips about hair growth.
Eventually, fearing the dreaded comb-over, he caved and got his first hair transplant in 2019 in Pakistan, where you can get the procedure for a fraction of what it costs in the West.
The results werent great, though, and the engineer ended up pursuing two more surgeries.
Now, no one would suspect he was an almost-balding guy once. Hes happy with his hair but wants people considering hair transplants to temper their expectations. Transplanted hair look will never be the same as your natural hair, he said, no matter where you do the transplant and how many you do.
With a hair transplant, you will think about the back side the donor area and the empty spaces there, he said. If you cut too much, it will be visible. You have to adopt a hairstyle that caters to where the density looks good.
Courtesy of Amir ur Rehman
Hair transplants arent the only option to explore
For most young men, the first action they take is typically topical treatments like minoxidil (Rogaine) and oral medications like finasteride (Propecia), which you take once a day.
These therapies can be effective in preserving hair and preventing further loss, but the only treatment to actually regrow hair where it is already balding is a hair transplant, Kieu said, pointing out to some new advancements in hair transplantation technology, like robotic hair restoration, where surgeons use AI to assist in the procedure.
This increases our efficiency while also minimizing scarring that we see in older techniques, she said.
For non-surgical hair restoration, Kieu said exosomes hair therapy has been an exciting newer development.
Exosomes are derived from stem cells, and they help with cell-to-cell signaling, which has powerful effects on cell function, she said. They contain growth factors, which stimulate your hair follicles to grow. Its a relatively quick procedure that we can do in-office in about 30 minutes with minimal downtime.
Hair restoration and preservation is definitely an investment in time and money. This is not the time to bargain shop.
- Monica Kieu, a plastic surgeon and hair restoration specialist in Newport Beach, California
Those procedures didnt exist when Spencer Stevenson, 47, got his first hair transplant about 20 years ago.
At the time, there was a dearth of information about hair transplants on the web. In fact, he found out about the clinic he ended up going to through a Super Bowl ad.
Before that, I looked in the Yellow Pages. I tried every single treatment that was available powders, paints, pills, lotions, all sorts of stuff which none of them worked, sadly, the Brit told HuffPost.
That led me to get an unfavorable hair transplant in the U.S., he said. I flew over from the U.K. to the U.S. and that resulted in really, really poor unnatural work.
Stevenson who goes by Spex Hair online and is something of a hair loss godfather, with quotes on BBC News, The Guardian and a radio advice show was left with scarring and dull hair on the top of his head.
After that first surgery, Stevenson had a few more unsuccessful surgeries. He lived under his hat; when hed take it off, his friends would make jabs about how the formerly follicularly blessed Stevenson was now prematurely balding.
Badgering is bad enough, but what makes it worse is that men are considered vain if they pursue cosmetic surgeries. People assume hair loss is just something you have to accept as part of the aging process. But as countless men and women on online forums like r/tressless will assure you, its not easy to watch globs of your hair collect in your shower drain when youre only 25.
The loss of my hair had a profound effect on me, on my self-esteem, Stevenson said. Hair loss is a cancer of the spirit, it traumatizes individuals and it really is a hidden epidemic.
Courtesy of Spencer Stevenson
Today, Stevenson has spent in the region of 40,000 pounds, which is close to 60,000 U.S. dollars, to try and restore and maintain his hair.
I would do it all over again. Its completely transformed my life now, he said. My motivation was purely to try and live a normal life and not an isolated one. I was consumed by my hair. It was the first thing I thought of when I woke up and the last thing I thought of when I went to bed.
Stevenson was so mentally scarred by his earlier work, he now co-hosts a radio show, The Bald Truth, to help people know what to look for in a hair specialist.
Im an advocate in this space because I want to protect consumers from making the same mistakes I made at first, he said. This industry is a ruthless space governed by money and taking advantage of the hapless hair loss sufferer.
Courtesy of Spencer Stevenson
How to do your research and avoid a long, drawn-out loss journey
So how do you have as seamless of a hair transplant surgery as possible?
When researching a hair transplant clinic, Kieu advises to look long and hard at before-and-after photos, and always check online reviews.
A board-certified physician should always be performing the procedure, and if possible, go to the clinic in-person for your consultation, so you can feel out the vibe, she said.
Turkey is probably the most common location outside the U.S. where patients go to have their hair transplants, but Kieu would caution people that prior research is important if they are going out of the country for a procedure.
I have heard of many horror stories of botched jobs, with no ability for any follow-up or recourse since the clinics are so far away and difficult to contact, she said, noting that as a specialist in hair restoration, about 20% of her practice is covering up scars from previous hair transplants or making obvious transplants look more natural.
Stevenson recommended looking for a reputable surgeon by looking through the International Alliance of Hair Restoration Surgeons.
Doctors on there have been screened, have been monitored and have an ethical moral duty to make sure people get the right work for them or even turn people away if not an eligible candidate, he said.
There are far more options in the hair restoration world than there were 20 years ago, when Stevenson was at his most desperate. Dont jump at the first option or try to financially cut corners with your head of hair.
As Kieu said and what all these guys stories attest to hair restoration and preservation is definitely an investment in time and money. This is not the time to bargain shop.
Follow this link:
Men Share The Costly Lengths They've Taken To Prevent Balding - HuffPost
Posted in Tennessee Stem Cells
Comments Off on Men Share The Costly Lengths They’ve Taken To Prevent Balding – HuffPost
Magnetic bandages with stem cells to be used to repair worn joints and mend broken bones… – The Sun
Posted: July 11, 2022 at 2:45 am
MAGNETIC bandages may soon be used to repair worn joints and mend broken bones.
Combining the dressings with an injection of stem cells helps cartilage and bone to regrow, researchers found.
1
The method, in which patients would recover at home, could spell the end of hip and knee replacement ops.
The NHS does about 100,000 of each every year, as well as spending 2billion on treating 850,000 broken bones.
The technique sees tiny magnetic particles attached to stem cells which are able to turn into bone and cartilage.
They are injected before being guided to the damaged areas and activated by the magnetic bandage.
In tests on sheep, the treatment sped up bone repair. Human trials are planned.
Prof Alicia El Haj, of Birmingham University, said the method worked better than existing treatments and would be quicker, cheaper and much less painful.
She said: You could have it in a GP clinic.
The breakthrough is being presented at the Royal Society summer science exhibition.
Read this article:
Magnetic bandages with stem cells to be used to repair worn joints and mend broken bones... - The Sun
Posted in Stem Cells
Comments Off on Magnetic bandages with stem cells to be used to repair worn joints and mend broken bones… – The Sun
3D Cell Culture Market to attain a valuation of US$ 2.67 Billion by 2031 – PharmiWeb.com
Posted: July 11, 2022 at 2:45 am
The3D cell culture marketrevenues surpassed US$ 778 million in 2018,as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,
Request Sample Copy of Report:https://www.futuremarketinsights.com/reports/sample/rep-gb-2843
The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.
Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material natural or synthetic and different mechanical properties.
The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.
According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.
While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years, says FMI.
Leading Manufacturers in the 3D Cell Culture Market:
Competitive Landscape of the Global 3D Cell Culture Market
The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.
The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.
Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.
Download PDF Brochure @https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843
Application of 3D Cell Culture in Cancer Research Prominent
The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.
2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.
Stem cell technology is another lucrative field for3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.
Revenues in North America Continue to Surge
North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.
Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.
Key SegmentBased on product type
Based on application
Based on end user
Explore Other Reports Links From Healthcare Market:
https://drujrake.mn.co/posts/24898121
https://tennispassion.mn.co/posts/24898141
https://skin-care-junkies.mn.co/posts/24898157
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.
Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs
Read the original post:
3D Cell Culture Market to attain a valuation of US$ 2.67 Billion by 2031 - PharmiWeb.com
Posted in Stem Cells
Comments Off on 3D Cell Culture Market to attain a valuation of US$ 2.67 Billion by 2031 – PharmiWeb.com
Next day CAR T cells effective and have acceptable safety in acute lymphoblastic leukaemia – Hospital Healthcare Europe
Posted: July 11, 2022 at 2:45 am
CAR T cells (CTC) which can be manufactured in a single day have been shown to be effective and with an acceptable safety profile, for the treatment of patients with relapsed or refractory B cell acute lymphoblastic leukaemia according to a first-in-human clinical study by a group of Chinese researchers.
Chimeric antigen receptor-engineered T cells (CAR T cells) represents a novel yet safe and effective therapy for B-cell acute lymphoblastic leukaemiapatients relapsing after an allotransplant. In CTC therapy, the patients own T cells are genetically engineered and then re-infused in an effort to eliminate their tumour cells.The T cells contain an extracellular ligand binding domain which is able to recognise antigens displayed on the surface of tumour cells (normally CD19). Moreover, it appears to be an effective form of therapy with one study from 2018 demonstrating complete remission in 83% of patients with relapsed B-cell acute lymphoblastic leukaemia. Nevertheless, as more clinicals have been undertaken, it has become evident that 30-60% patients relapse after treatment, probably due to persistence of CAR T-cells and escape or down-regulation of CD19 antigen. A further problem is that the T-cell engineering process can take 9 to 14 days and up to four weeks before infusion back into the patient.
For the present study, the Chinese team developed a type of CAR T cells that were manufactured using a novel process completed in 24 hours. The final product CTC product, GC007F was tested in patients with relapsed or refractory B cell acute lymphoblastic leukaemia and for comparative purposes, the researchers also manufactured CTCs by conventional methods.
CAR T cells and patient outcomes
A total of 21 patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukaemia were enrolled and given a single infusion of GC007F cells although only 18 were included in the final analysis after the others withdrew due to adverse effects. The median peak of CAR T cells was on day 10 and the median persistence was 56 days. The GC007F cells also showed better proliferation and tumour killing than conventional CTCs.
After 28 days, all patients had achieved complete remission (CR), with 17 achieving CR and maintaining minimal residual disease negative, MRD (i.e., no disease was detected after treatment) after 3 months. Additionally, at 6 months, 16 patients maintained CR with 14 maintaining MRD negative and the longest duration at the time of writing was 29 months without the need for transplant.
In terms of safety, 95.2% (n = 20) of patients experienced cytokine release syndrome (a recognised adverse effect) and which was greater than grade 3 (i.e., severe) in 52.4% (11) of patients. Neurotoxicity developed in 6 patients and was greater than grade 3 severity in 3 patients.
Overall, eight patients underwent allogeneic haematopoietic stem cell transplantation after GC007F treatment.
The authors concluded that these preliminary data suggested that their next day GC007F cells appeared to be effective and with a manageable toxicity profile.
CitationZhang C et al. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia Blood Cancer J 2022
Posted in Stem Cells
Comments Off on Next day CAR T cells effective and have acceptable safety in acute lymphoblastic leukaemia – Hospital Healthcare Europe
Rare Disease Genetic Testing Market 2022 Emerging Trends, Comprehensive Study With Top Companies and Key Players till 2030 – Taiwan News
Posted: July 11, 2022 at 2:44 am
Key Companies Covered in the Rare Disease Genetic Testing Market Research are Quest Diagnostics Inc., Centogene N.V., Invitae Corporation, 3billion, Inc., Arup Laboratories, Eurofins Scientific, Strand Life Sciences, Ambry Genetics, Perkin Elmer, Inc., Macrogen, Inc. and other key market players.
Global Rare Disease Genetic Testing Market is valued approximately USD 0.9186 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 10.9% over the forecast period 2021-2027.
Rare Disease Genetic Testing is a test which presents the range of all the genes which are currently known to cause human disease. There are about 6000 genes which reported to be clinically relevant. These genes contains a select set of genes or gene region which are suspected to have relationship with certain diseases.
Request To Download Free Sample of This Strategic Report: https://www.quadintel.com/request-sample/rare-disease-genetic-testing-market/QI037
This lead to a rise in the number of already present genes and as a result it further increased the market growth opportunity for this sector as it allows to collect sufficient amount of data which enables to continue clinical research for future discoveries. These diseases possess a threat to the mankind and needs to be diagnosed timely and accurately. This proves to be a driving factor for the market. The lack of awareness to these conditions is a primary challenge for the market. The Misdiagnosis of the diseases can result in interventions which could later be considered inappropriate for the underlying disorder. Therefore there is an urgent need to raise awareness about the aspects of these diseases like the challenges concerning with regard to diagnosis and clinical implementation of available diagnostic ways. Along with all the above stated factors technological advancements in collection of data and interpretation for clinical practice has also driven the market. Various efforts have been made by the market players in order to collect data from different ethnicities.
The regional analysis of global Rare Disease Genetic Testing Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leader in Genetic Testing Market with an overall share of 47% of the total market in 2019.There will be a surge in the number of patients in the coming years this will further allow the market to grow. On the other hand, Asia Pacific is expected to grow more significantly in the coming years due to the increased awareness and rising populations in the Asian countries.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
Download Free Sample Report, SPECIAL OFFER (Avail an Up-to 30% discount on this report) https://www.quadintel.com/request-sample/rare-disease-genetic-testing-market/QI037
The detailed segments and sub-segment of the market are explained below:
By Type:
Neurological DisordersImmunological DisordersHematology DiseasesEndocrine & Metabolism DiseasesCancerMusculoskeletal DisordersCardiovascular DisordersDermatology DiseasesOther Rare Diseases
By Technology:
Next Generation SequencingArray TechnologyPCR based TestingFISHSanger SequencingKaryotyping
By Specialty:
Molecular Genetic TestsChromosomal Genetic TestsBiochemical Genetic Tests
By End-use:
Research Laboratories & CROsHospitals & ClinicsDiagnostic Laboratories
By Region:North Americao U.S.o CanadaEuropeo UKo Germanyo Franceo Spaino Italyo ROE
Asia Pacifico Chinao Indiao Japano Australiao South Koreao RoAPACLatin Americao Brazilo MexicoRest of the World
Furthermore, years considered for the study are as follows:
Historical year 2018, 2019Base year 2020Forecast period 2021 to 2027
Target Audience of the Global Rare Disease Genetic Testing Market in Market Study:
Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors
Request full Report Description, TOC, Table of Figure, Chart, etc.@ https://www.quadintel.com/request-sample/rare-disease-genetic-testing-market/QI037
Table of content
What is the goal of the report?
The market report presents the estimated size of the Market at the end of the forecast period. The report also examines historical and current market sizes. During the forecast period, the report analysis the growth rate, market size, and market valuation. The report presents current trends in the industry and the future potential of the North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa markets. The report offers a comprehensive view of the market based on geographic scope, market segmentation, and key player financial performance.
What is the key information extracted from the report?
Request Full Report https://www.quadintel.com/request-sample/rare-disease-genetic-testing-market/QI037
About Quadintel:
We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Quadintel is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.
Get in Touch with Us:
Quadintel:Email: sales@quadintel.comAddress: Office 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATESTel: +1 888 212 3539 (US TOLL FREE)Website: https://www.quadintel.com/
Originally posted here:
Rare Disease Genetic Testing Market 2022 Emerging Trends, Comprehensive Study With Top Companies and Key Players till 2030 - Taiwan News
Posted in Molecular Genetics
Comments Off on Rare Disease Genetic Testing Market 2022 Emerging Trends, Comprehensive Study With Top Companies and Key Players till 2030 – Taiwan News
Proteases implicated in ulcerative colitis – ASBMB Today
Posted: July 11, 2022 at 2:44 am
Ulcerative colitis, or UC, is a form of inflammatory bowel disease characterized by chronic and relapsing large intestine inflammation. Genetics account for only a minority of UC cases; hence, to develop treatments, researchers need to understand better the environmental contributions to this condition.
Gut microbes are in perpetual contact with the gastrointestinal tract, so they comprise important but poorly defined environmental variables contributing to UC development. Many studies have reported changes in gut microbiome composition in patients with UC compared to healthy individuals. While that suggests a potential role for gut microbes in UC pathogenesis, researchers have yet to pinpoint the causative microbes and associated bacterial proteins.
Dennis Wolans lab at Scripps Research is interested in identifying small-molecule activators and inhibiting bacterial enzymes involved in proliferation of human disease. Wolan said he was curious about what bacterial enzymes of the microbiome contribute to UC development.
Many publications have focused on the role of the microbiome in both health and disease states, he said. Most of these were focused on the taxonomical and phylogenic differences in the microbiome. But what about the associated bacterial proteins? What proteins are these gut bacteria making in disease conditions, and how are these interacting with the human body?
One protein of interest was serine proteases, a type of proteolytic enzyme that cleaves peptides at the serine amino acid. Researchers long have recognized that they coordinate many physiological processes and play key roles in regulating the inflammatory response. Previous studies have suggested increased proteolytic activity in microbial samples harvested from people with inflammatory disorders such as UC and Crohns disease.
Peter ThuyBuon, a graduate student and later a postdoc in the Wolan lab, led a project to study differential protein expression in healthy and UC fecal samples. He and the team described the project in a recent paper in the journal Molecular & Cellular Proteomics. In addition to standard mass spectrometry, ThuyBuon used a small molecular approach called affinity-based proteomic profiling to target and enrich for different types of proteases in the fecal samples.
We showed that there were 176 discrete host and microbial protein groups differentially enriched between healthy and UC patients, Wolan said. Furthermore, further enrichment of these proteins showed significantly higher levels of serine proteases in UC patients.
This finding has inspired exciting future research questions. For example, are elevated serine proteases the driver of UC or merely the effect of UC disease progression?
There is a lot of exciting work to be done using these findings, Wolan said. Future molecular studies should focus on how serine proteases might be contributing to UC and whether their levels can be manipulated to modify disease progression.
Functional proteomics has shown the potential role of serine proteases in UC. Future steps will include drug discovery and design of small-molecule regulators of bacterial enzymes.
Wolan said, Ultimately, the moderation of microbiome distribution in UC via external small-molecule intervention can serve as a foundation for UC prevention and treatment.
Go here to see the original:
Proteases implicated in ulcerative colitis - ASBMB Today
Posted in Molecular Genetics
Comments Off on Proteases implicated in ulcerative colitis – ASBMB Today
